436.90
+4.70%
Close of 9 Nov 2026, in INR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Syngene International
Its shares trade on NSE under the ticker SYNGENE.NS. It has been listed since 11 August 2015. In the fiscal year to 31 March 2026, it reported revenue of ₹37.39bn and net income of ₹3.17bn. At that date it held total assets of ₹70.55bn and shareholders' equity of ₹48.39bn.
Syngene International Ltd. operates as a global discovery, development and manufacturing organization providing integrated scientific services to the pharmaceutical, biotechnology, nutrition, animal health, consumer goods and specialty chemical industries. The company is headquartered in Bangalore, Karnataka. The company went IPO on 2015-08-11. The firm is engaged in providing services from early discovery and development to commercial manufacturing for small and large molecules. Its services include drug discovery and development capabilities in medicinal chemistry, biology, in vivo pharmacology, toxicology, custom synthesis, process research and development, current good manufacturing practice (cGMP) manufacturing, formulation and analytical development along with clinical development services. The company offers SynVent, a therapeutic discovery and development platform for executing drug discovery projects, which is designed to provide a range of advance programs through target validation, translational interrogation, therapeutic discovery and preclinical development for both large and small molecules, as well as specialty modalities, such as targeted protein degradation. The company serves clients ranging from multinational corporations to start-ups.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Life Sciences Tools & Services
- Listed since
- 11 Aug 2015
- Employees
- 5,975
- Website
- syngeneintl.com ↗
Leadership
Pay as last reported
- Dr. Kiran Mazumdar ShawNon-Executive Chairman of the Board, since 2020₹9.9m
- Mr. Peter BainsChief Executive Officer, Managing Director, Additional Director, since 2010
- Mr. Deepak JainChief Financial Officer
- Mr. Andrew WebsterChief Human Resources Officer
- Dr. Kenneth BarrSenior Vice President - Research Services, since 2024
- Mr. Alex Del PrioreSenior Vice President - Manufacturing Services
- Mr. Gaurav KushwahaChief Technology Officer
- Dr. Jayashree AiyarChief Scientific Officer
- Mr. Chethan YogeshCompliance Officer, Company Secretary
- Mr. Pramuch GoelHead of Corporate Affairs
- Ms. Caroline HempsteadHead of Customer Centricity and Special Projects
- Mr. Alok MehrotraChief Quality Officer
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 93
- Environment
- 99
- Social
- 99
- Governance
- 81
- Direct emissions (scope 1)
- 6,653 t
- Energy emissions (scope 2)
- 73,850 t
- Value chain emissions (scope 3)
- 48,768 t
- Women in the workforce
- 26%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Established name in the pharmaceutical industry.
- Strong partnerships with leading global biotech and pharmaceutical companies.
- Wide range of services spanning across discovery, development, and manufacturing.
- State-of-the-art research facilities and infrastructure.
- Highly skilled and experienced workforce.
Weaknesses
- Dependency on a limited number of key clients for a significant portion of revenue.
- Vulnerability to changes in government policies and regulations.
- Relatively lower brand recognition compared to some competitors.
- Limited geographical presence outside of India.
- Potential impact from fluctuations in currency exchange rates.
Opportunities
- Growing demand for contract research and manufacturing services in the pharmaceutical industry.
- Increasing adoption of biologics and specialty molecules, providing new avenues for growth.
- Expansion into untapped markets in Asia, Africa, and the Middle East.
- Collaboration opportunities with emerging biotech firms and startups.
- Potential to develop innovative solutions for personalized medicine and targeted therapies.
Threats
- Intense competition from both domestic and international contract research organizations.
- Regulatory challenges and compliance requirements in the pharmaceutical industry.
- Rapidly evolving technology landscape necessitating continuous investments in research and development.
- Geopolitical uncertainties impacting global business operations.
- Economic fluctuations and market volatility affecting client spending on research and development.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.